974TiP Exploratory phase Ib/IIa study of intratumorally administered tigilanol tiglate to assess safety, tolerability and tumour response in patients with head and neck squamous cell carcinoma

Authors :: A. Pattatheyil
V. Gordon
C.M.E. Barnett
G.H. Pantvaidya
Richard Gallagher
A.D. Deshmukh
T.L. Mynott
D.J. Swart
A. Cleal
R. Sharan
Benedict Panizza
Amy Prawira
Source :: Annals of Oncology. 31:S684
Publication Year :: 2020
Publisher :: Elsevier BV, 2020.

Subjects :: Oncology
medicine.medical_specialty
business.industry
Safety tolerability
Hematology
Exploratory phase
medicine.disease
Tumour response
Head and neck squamous-cell carcinoma
Tigilanol tiglate
chemistry.chemical_compound
chemistry
Internal medicine
Medicine
In patient
business

Tools